ProfileGDS5678 / 1437627_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 74% 73% 80% 74% 73% 74% 71% 74% 82% 74% 74% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8193774
GSM967853U87-EV human glioblastoma xenograft - Control 24.8237174
GSM967854U87-EV human glioblastoma xenograft - Control 34.815974
GSM967855U87-EV human glioblastoma xenograft - Control 44.8008273
GSM967856U87-EV human glioblastoma xenograft - Control 55.6297880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6995174
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6889573
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8088674
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.454871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8207974
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8561182
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9222974
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.820274
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3879778